Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%
Market cap
$3.6B
P/E
17.4×
Fwd P/E
5.2×
Dividend yield
0.58%
F-score
5/9
Altman Z
1.09
Beneish M
−2.68
Dividend safety
45/100
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 4 5 4 5 5
P/E ratio
4.54 4.54 4.54 4.54 5.71 7.80 3.66 4.45 9.96
Altman Z-Score
— — — — 1.52 1.51 1.26 1.27 1.09
P/S ratio
1.35 1.35 1.35 1.35 1.22 1.16 0.60 0.60 0.30
Altman Z″-Score (non-manufacturers)
— — — — 1.41 1.64 1.68 1.81 1.78
P/FCF ratio
3.39 3.39 3.39 3.39 3.91 13.09 8.29 5.78 4.48
Beneish M-Score
— — — (2.93) (3.56) (2.40) (2.21) (2.62) (2.68)
P/Operating CF
6.48 6.48 6.48 6.48 164.26 26.71 9.46 9.83 13.20
Dividend Safety Score
— — — — — — — — 45
P/B ratio
1.79 1.79 1.79 1.79 0.00 0.00 0.00 8.13 2.47
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
1.49 1.49 1.49 1.49 2.56 2.48 1.89 1.88 1.60
EV/EBITDA
3.75 3.75 3.75 3.75 8.38 8.61 7.92 7.24 6.92
EV/Operating CF
3.40 3.40 3.40 3.40 7.46 17.88 14.80 12.82 14.19
EV/FCF
3.76 3.76 3.76 3.76 8.16 28.15 26.10 18.16 23.93
Quick Ratio
— 1.20 1.34 0.39 0.82 0.87 0.84 0.75 0.80
Current Ratio
— 2.40 2.95 1.33 1.45 1.56 1.54 1.60 1.82
Net Debt/EBITDA
0.00 (0.02) (0.05) 0.01 4.69 4.61 5.40 4.94 5.62
Debt/Assets
0.00% 0.00% 1.12% 0.31% 85.52% 81.36% 72.65% 67.78% 67.18%
Debt/Equity
— 0.00 0.02 0.01 (6.06) (9.99) (125.14) 18.81 11.49
Asset Turnover
0.00 0.00 1.47 0.63 0.61 0.57 0.54 0.51 0.48
Operating CF/Net income
1.90 1.71 0.94 1.06 1.60 0.94 0.78 1.09 3.74
Capex/Depreciation
0.00 (0.04) (0.26) (1.76) (1.93) (1.48) (1.07) (0.96) (0.47)
Interest Coverage
261.76 129.95 194.53 174.75 6.94 3.72 2.39 2.64 1.63
ROE
0.00% 32.18% 48.09% 34.50% 67.92% (76.42%) (212.68%) 429.85% 30.56%
ROA
0.00% 0.00% 61.02% 20.91% 13.00% 8.48% 8.89% 6.87% 1.44%
ROIC
— 0.00% 33.80% 31.74% 16.25% 13.41% 9.82% 9.90% 5.84%
Return on Tangible Assets
0.00% 76.35% 97.69% 115.02% 63.25% 37.63% 36.89% 30.88% 5.73%
Average Days of Receivables
0.00 59.92 69.18 58.00 80.02 87.20 101.64 77.41 78.16
Research and Development Expense of Revenue
3.38% 3.73% 2.83% 3.21% 5.38% 7.63% 8.43% 7.32% 5.89%
Selling, General and Administrative Expense of Revenue
21.76% 20.59% 18.55% 20.76% 26.46% 27.60% 30.23% 27.49% 27.69%
Intangible Assets out of Total Assets
0.00 0.00 0.49 0.51 0.49 0.48 0.43 0.47 0.41
Share Based Compensation of Revenue
0.00% 0.57% 0.53% 0.61% 0.94% 1.21% 1.61% 1.64% 1.24%
Graham Net Nets
(0.23) (0.23) (0.23) (0.23) (1.09) (1.11) (2.03) (2.16) (4.17)
Graham Number
0.00 0.00 0.00 64.41 0.00 0.00 0.00 11.76 6.85
Earnings Yield
22.04% 22.04% 22.04% 22.04% 17.50% 12.83% 27.33% 22.45% 10.04%
Free Cash Flow Yield
29.46% 29.46% 29.46% 29.46% 25.58% 7.64% 12.07% 17.29% 22.30%
Revenue per Share
41.50 38.64 30.68 25.77 24.86 24.30 24.54 24.91 23.95
Operating CF per Share
13.51 14.57 11.91 9.01 8.52 3.38 3.13 3.65 2.70
Capex per Share
0.00 (0.27) (0.35) (0.99) (1.49) (1.23) (0.99) (1.07) (1.10)
Free Cash Flow per Share
13.51 14.30 11.57 8.02 7.03 2.15 2.14 2.58 1.60
Cash per Share
0.00 0.96 1.26 0.05 2.91 2.78 2.72 2.63 2.21
Shareholders Equity per Share
0.00 0.00 27.75 21.64 (5.95) (3.51) (0.27) 1.84 2.90
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 27.75 21.64 (5.95) (3.51) (0.27) 1.84 2.90
Free Cash Flow
3,419.00 3,618.00 2,932.00 2,034.00 1,783.00 545.00 547.00 663.00 415.00
Working Capital
— 2,169.00 2,614.00 894.00 1,163.00 1,419.00 1,590.00 1,630.00 1,962.00
Capital Expenditures
(86.00) (69.00) (88.00) (250.00) (377.00) (313.00) (252.00) (276.00) (285.00)
Net Current Asset Value
— 3,714.00 442.00 (1,056.00) (8,429.00) (7,916.00) (7,620.00) (8,281.00) (7,763.00)
EV/EBIT
4.01 4.01 4.01 4.01 9.00 9.77 9.40 8.76 12.05
Capex to Sales
0.00 0.01 0.01 0.04 0.06 0.05 0.04 0.04 0.05
Price to Operating Income
3.63 3.63 3.63 3.63 4.31 4.54 2.99 2.79 2.26
Other line items
Depreciation/Fixed assets
0.00 2.57 0.49 0.14 0.20 0.21 0.20 0.25 0.47
Cash ROIC
0.00% 920.61% 39.24% 36.79% 21.32% 6.24% 5.83% 6.61% 4.16%
Accounts Receivable Turnover
0.00 6.35 5.05 5.20 5.21 4.32 3.89 4.13 4.62
Accounts Payable Turnover
0.00 17.16 8.31 8.20 2.90 1.83 2.06 2.18 2.76
Inventory Turnover
0.00 4.55 2.20 2.14 2.61 2.39 2.17 2.04 2.13
Average Days of Payables
0.00 22.48 41.41 44.61 211.77 180.11 190.70 156.56 119.70
Days of Inventory on Hand
0.00 77.31 171.91 157.27 140.21 159.59 190.84 179.38 176.78
Average Receivables
— 1,539.50 1,539.50 1,256.00 1,210.00 1,428.50 1,609.50 1,551.00 1,344.50
Average Payables
— 273.50 273.50 258.50 820.50 1,257.00 1,223.00 1,233.50 1,052.50
Average Inventory
— 1,032.50 1,032.50 992.00 914.00 959.00 1,159.00 1,318.00 1,363.50
Average Assets
— 0.00 5,274.00 10,328.50 10,395.00 10,818.00 11,506.50 12,579.50 12,984.00
Average Common Equity
— 6,691.50 6,691.50 6,260.50 1,989.00 (1,200.00) (481.00) 201.00 612.00

Fold the line items

Columns are period end dates